Published in final edited form as:

Hippocampus. 2015 September ; 25(9): 1042–1051. doi:10.1002/hipo.22427.

Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects

Matthew J. Smith, Ph.D., LCSW, MPE^{a,b}, Derin J. Cobia, Ph.D.^{a,b}, James L. Reilly, Ph.D.^{a,b}, Jodi Gilman, Ph.D.^c, Andrea G. Roberts, B.A.^{a,b}, Kathryn I. Alpert, B.S.^a, Lei Wang, Ph.D.^{a,c,e}, Hans C. Breiter, M.D.^{a,b,e}, and John G. Csernansky, M.D.^{a,e}

^aNorthwestern University Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences

^bNorthwestern University Feinberg School of Medicine, Warren Wright Adolescent Center

^cDepartment of Radiology

^dCenter for Addiction Medicine, Massachusetts General Hospital

Abstract

Cannabis use has been associated with episodic memory (EM) impairments and abnormal hippocampus morphology among both healthy individuals and schizophrenia subjects. Considering the hippocampus' role in EM, research is needed to evaluate the relationship between cannabis-related hippocampal morphology and EM among healthy and clinical groups. We examined differences in hippocampus morphology between control and schizophrenia subjects with and without a past (not current) cannabis use disorder (CUD). Subjects group-matched on demographics included 44 healthy controls (CON), 10 subjects with a CUD history (CON-CUD), 28 schizophrenia subjects with no history of substance use disorders (SCZ), and 15 schizophrenia subjects with a CUD history (SCZ-CUD). Large- deformation, high-dimensional brain mapping with MRI produced surface-based representations of the hippocampus that were compared across all four groups and correlated with EM and CUD history. Surface maps of the hippocampus were generated to visualize morphological differences. CON-CUD and SCZ- CUD were characterized by distinct cannabis-related hippocampal shape differences and parametric deficits in EM. Shape differences observed in CON-CUD were associated with poorer EM, while shape differences observed in SCZ-CUD were associated with a longer duration of CUD and shorter duration of CUD abstinence. A past history of CUD may be associated with notable differences in hippocampal morphology and EM impairments among adults with and without schizophrenia. Although the results may be compatible with a causal hypothesis, we must consider that the observed cannabis-related shape differences in the hippocampus could also be explained as biomarkers of a neurobiological susceptibility to poor memory or the effects of cannabis.

Corresponding Author: Dr. Matthew J. Smith, Northwestern University Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, 710 N. Lake Shore Drive, 13th Floor Abbott Hall, Chicago, IL 60611. Phone: 1-312-503-2542, Fax: 1-312-503-0527, matthewsmith@northwestern.edu.

^eequal contributions by senior authors

The authors declare no conflict of interest.

Keywords

Hippocampus; Marijuana; Neuroimaging; Morphology; Shape Analysis

Introduction

Over the past decade policy makers have redefined state laws surrounding cannabis use in the United States, including the decriminalization or legalization of cannabis possession for medical and recreational purposes. In 2010, the National Survey on Drug Use and Health (SAMSHA, 2011) identified cannabis as the most commonly used illicit drug in the United States and recent policy changes regarding cannabis in Colorado resulted in an increased prevalence of cannabis abuse and a decrease in perceived risk of cannabis use among adolescents (Schuermeyer et al., 2014). Based on recent evidence that cannabis use beginning in adolescence has been linked to cognitive deficits, it is important to evaluate the relationship between cannabis use and the morphology of brain structures underlying specific cognitive functions.

Cannabis use and the acute administration of delta-9-tetrahydrocannabinol (Δ^9 -THC) (a CB1 receptor agonist and main psychoactive compound in cannabis) have been associated with impairments in episodic memory (EM) (see (Crane et al., 2013; Ranganathan and D'Souza, 2006) for review), the type of memory associated with autobiographical events (Stark, 2007). Limbic structures, in particular the hippocampus, play an integral role in memory formation and are characterized by a high density of cannabinoid type 1 (CB1) receptors (Svizenska et al., 2008). Cannabis use disrupts memory by overactivating CB1 receptor expression in the hippocampus which inhibits glutamateric and GABAergic neurotransmission and suppresses LTP and LTD (Navakkode and Korte, 2014).

Recent evidence suggests that heavy cannabis users had altered hippocampal morphology (Ashtari et al., 2011; Medina et al., 2007; Solowij et al., 2013; Yucel et al., 2008) that was related to cannabis use history (e.g., age of onset, duration of use). Specifically, reduced hippocampal volume and shape differences were correlated with recent and overall duration of cannabis use (Ashtari et al., 2011; Solowij et al., 2013). However, these recent findings differ from older studies looking at hippocampal volume differences between users and non-users (Block et al., 2000; Tzilos, 2005). Moreover the relationship between cannabis-related hippocampal morphology and cognition remains unclear. Accordingly, we sought to evaluate whether cannabis-related alterations in hippocampal morphology were associated with impaired EM performance.

Schizophrenia is frequently characterized by EM impairments (Leavitt and Goldberg, 2009) as well as anatomical abnormalities in the hippocampus (Heckers and Konradi, 2010; Schobel et al., 2009). Individuals with schizophrenia also demonstrate exacerbated EM impairments related to the acute administration of THC (Henquet et al., 2006); however, the literature on long-term cannabis use and cognition in schizophrenia is less clear (Yucel et al., 2012). Prior research found that cannabis-related differences in hippocampal morphology among individuals with schizophrenia were associated with the pattern of cannabis use (Solowij et al., 2013). However, the association between these differences and

EM performance has not been explicitly examined in this clinical population. Further study of individuals with schizophrenia provides an ideal opportunity to examine the relationship among cannabis, hippocampal morphology, and EM in a clinical population.

The current study used structural imaging methods in order to determine whether a past CUD was associated with volumetric or shape differences in the hippocampus, and whether such differences were associated with EM deficits. Based on prior work (Smith et al., 2014), we studied the hippocampus in two ways. We evaluated hippocampal morphology and EM performance in (i) controls and a matched group with a prior history of a cannabis use disorder (CUD) and (ii) in schizophrenia subjects with known EM deficits and a subset of this group with CUD. This approach allows a 2×2 assessment of combined cannabis and illness-associated EM deficits, as well as whether common cannabis-related associations exist among the control and clinical groups through testing of the following hypotheses: (1) healthy subjects with past CUDs (i.e., history of cannabis abuse or dependence, but not during the past 6 months) (CON-CUD) would demonstrate morphological differences in the hippocampus compared with healthy controls (i.e., subjects with no history of any substance use disorder) (CON); (2) schizophrenia subjects with a past CUD and no history of other substance use disorders (SCZ-CUD) would be characterized by (a) hippocampal differences that are consistent with the morphology observed in CON-CUD, (b) morphological differences in regions implicated in schizophrenia, but not in CON-CUD, and (c) exaggerated morphological differences in regions that have been linked to both schizophrenia and CON-CUD; (3) schizophrenia subjects with no history of a substance use disorder (SCZ) would be characterized by hippocampal differences that are consistent with prior studies; (4) CON-CUD and SCZ-CUD would have poorer EM performance than CON and SCZ, respectively; and (5) morphological differences characterizing the CUD groups would correlate with poorer EM performance, a greater duration of CUD abuse and shorter duration of CUD abstinence.

Materials and Methods

Participants

Subjects included 44 CON, 10 CON-CUD, 28 SCZ, and 15 SCZ-CUD subjects group-matched on age, gender, handedness (Oldfield, 1971), and parental socioeconomic status (Hollingshead, 1975) who underwent neuroimaging and cognitive testing as part of their participation in a large cross-sectional neurobiological study of schizophrenia. These subjects are a subset of individuals from a prior study that provides in depth details on their characteristics and patterns of substance use (Smith et al., 2014). One CON subject from the prior sample had a poor quality scan of the hippocampus and was replaced by a subject selected from a large pool of available healthy controls with matched gender and handedness in order to achieve the same statistical power as the prior study (Karnik-Henry et al., 2012).

Subjects were recruited from the community by advertising in local psychiatric clinics and surrounding neighborhoods. The institutional review board at Washington University in St. Louis and Northwestern University Feinberg school of Medicine approved the study protocol and all subjects provided informed consent.

Clinical Measures

Clinical interviews using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) (First et al., 2002) obtained the psychiatric and substance use history of study subjects. The combination of SCID findings, a psychiatric evaluation, family report, and current medical records determined the diagnosis of schizophrenia, major depressive disorder, or an anxiety disorder (i.e., generalized anxiety disorder, social anxiety disorder, or panic disorder) and provided information regarding the duration of illness and lifetime history of abuse or dependence for cannabis, alcohol, cocaine, opioids, hallucinogens, stimulants, and sedatives. Subjects classified as having a “past substance use disorder” met SCID criteria for abuse or dependence greater than 6 months before enrolling in the study. SCID data also provided frequency of marijuana use (daily or weekly), and age of CUD onset, duration of CUD, and duration of remission.

Self-reported treatment with typical and atypical antipsychotic medications were computed into chlorpromazine dose-years using a standard method (Andreasen et al., 2010), while nicotine use (past year) was estimated using a semi-structured interview detailed here (Smith et al., 2008). Psychopathology was assessed using global ratings from the Scale of the Assessment of Positive Symptoms (Andreasen, 1983b) and the Scale of the Assessment of Negative Symptoms (Andreasen, 1983a).

Cognitive Measures

The Vocabulary subtest from the Wechsler Adult Intelligence Scale – Third Edition (Wechsler, 1997a) was used as a measure of verbal intellect and as an estimate of premorbid functioning (Schoenberg et al., 2003). Memory performance in all subjects was evaluated using standard neuropsychological paradigms that measure the encoding and retrieval components of EM. As part of a larger neuropsychological battery, the Logical Memory II subtest from the Wechsler Memory Scale-Third Edition (Wechsler, 1997) was used to assess delayed recall of organized verbal information. Five subjects did not complete the Logical Memory II subtest (1 CON-CUD, 2 SCZ, and 2 SCZ-CUD). A group-level mean imputation replaced the missing data (Enders, 2010).

Imaging Acquisition

Magnetic resonance (MR) scans were collected with a standard head coil on a 1.5-Tesla Siemens VISION (Erlangen, Germany) scanner using a Fast Low-Angle Shot sequence (3D FLASH: TR=20msec, TE=5.4msec, flip angle=30°, 180slices, matrix=256×256, voxel resolution=1mm³ isotropic) (Venkatesan and Haacke, 1997). To control for total brain volume, we calculated an atlas scaling factor (ASF) for each individual. (Buckner et al., 2004). The ASF is the reciprocal of the determinant of the alignment matrix to Talairach atlas space and signifies the extent that brain volume contracts or expands during alignment to atlas space.

Surface Mapping

Hippocampal surfaces were derived through application of Large-Deformation High-Dimensional Brain Mapping (Csernansky et al., 2004). This is an atlas-based transformation technique where a previously generated template image is first aligned with the target

regions in each subject via anatomical landmarks, and then warped onto the target via diffeomorphic mapping of voxel intensities. Finally, hippocampal surfaces with corresponding vertices were generated for all subjects by applying the transformations to a previously tessellated template surface (Csernansky et al., 2004). Hippocampal volume was derived from the space enclosed within the surface.

To assess shape, hippocampal surfaces from subjects' native space were first rigidly aligned into a previously established template space (Csernansky et al., 2004), and a population average was generated. A principal components analysis was then performed on the aligned left and right surfaces. The principal components (PCs) represented variations in the shape of the left and right surfaces. The first ten PCs accounted for more than 80% of the total shape variance and were used in subsequent statistical analyses.

To visualize between-group shape differences, we calculated a T score at each surface vertex between the group of interest and a reference group and then color-coded the T scores on the average surface of the reference group.

Data Analysis

We conducted repeated measures analysis of variance models (RM-ANOVA) with hemisphere as a within-group effect and group membership as a between-subject factor to assess group, group-by-hemisphere, group-by-PC, and group-by-PC-by-hemisphere effects in hippocampal shape across all four groups. Based on these 5 tests, we used a corrected threshold of $p = 0.01$ ($0.05/5$) for the RM-ANOVA assessing shape. Then we conducted between-group RM-ANOVAs as post-hoc tests for (1) CON-CUD vs. CON, (2) SCZ vs. CON, (3) CON-CUD vs. SCZ, and (4) SCZ-CUD vs. SCZ. Nicotine use and the atlas scaling factor (i.e., total brain volume) were examined as covariates. Dose years of second generation antipsychotic treatment were also examined as covariates given prior research suggests that antipsychotic treatment is associated with changes in gray matter volume (Fusar-Poli et al., 2013; Lesh et al., 2015; Vita et al., 2012).

We also compared total hippocampal volume between group pairings using RM-ANOVA with group and hemisphere as fixed effects. Based on these 2 tests, we used a corrected threshold of $p = 0.025$ ($0.05/2$) for the RM-ANOVA assessing volume. We examined demographic, clinical, and EM variables across all subjects with ANOVAs to determine the significance of between-group differences. We reference the shape and volumetric differences observed in CON-CUD compared to CON and in SCZ-CUD compared to SCZ as “cannabis-related.”

Between-group differences on clinical, EM, and morphology measures were evaluated using ANOVA and characterized using p -values and Cohen's effect sizes (d). Based on our directional hypotheses supported by prior work (Smith et al., 2014), we computed one-tailed Pearson correlation coefficients between hippocampal shape and volume and EM performance, symptoms, and the CUD history variables (i.e., age of onset, duration of CUD, duration of remission from CUD). To correlate shape differences with EM and cannabis use history, a maximum likelihood estimate of the linear predictor (i.e., $x\beta$) for each subject was generated from a logistic regression procedure. The $x\beta$ was based on the 10 PCs

representing overall shape, and was used to examine the relation between shape and EM and shape and CUD history. Intellectual function was utilized as a covariate as groups differed on this measure.

Results

Participant Characteristics

The ANOVAs revealed that groups did not differ with respect to age, gender, handedness, and parental socioeconomic status, while SCZ and SCZ-CUD did not differ with respect to a lifetime co-morbid diagnosis of major depressive disorder or an anxiety disorder ($p > 0.10$) (Table 1). Nicotine use and verbal IQ differed across all groups ($F_{3,93}=3.7, p = 0.05$ and $F_{3,93}=8.8, p = 0.001$, respectively). Nicotine and verbal IQ were included as covariates in the shape and correlation analyses so the results can be interpreted above and beyond the potential effects of nicotine and a global measure of intelligence (Brody et al., 2004; Jubelt et al., 2008; Schumann et al., 2007),

As reported in Smith et al., 2014, the two CUD groups did not differ with respect to duration of CUD ($M=2.6$ years, $SD=2.5$) and duration since cannabis abstinence ($M=2.4$ years, $SD=1.7$). Sixty percent or greater of all subjects with a former CUD diagnosis met criteria for dependence, while eighty percent (or greater) of these same subjects reported daily cannabis use. The typical and atypical antipsychotic medication dose-years did not differ between the two SCZ groups ($F_{1,41}=0.3, p = 0.10$ and $F_{1,41}=2.6, p = 0.10$, respectively).

Hippocampus Shape

RM-ANOVA across all groups revealed a main effect for group ($F_{3,90}=4.2, p = 0.01$), a group-by-PC interaction ($F_{9,84}=2.6, p = 0.01$), and a PC-by-total brain volume interaction ($F_{9,82}=6.5, p = 0.001$), all meeting the correction for multiple comparisons. Trend-level effects were observed for hemisphere ($F_{1,90}=3.0, p=0.09$) and the group-by-hemisphere interaction ($F_{3,90}=2.4, p=0.07$).

Posthoc differences between CON-CUD and CON revealed a main effect for group ($F_{1,49}=7.4, p=0.011$), but the group-by-PC interactions were non-significant (both $p>0.10$). Figure 1A visualizes the shape differences between-groups. The flame scale reflects T-values with cooler colors ($T<0$) indicating inward shape differences and warmer colors ($T>0$) reflecting outward shape differences. CON-CUD were characterized by inward differences in the anterior hippocampus as well as the mediodorsal and medioventral regions of the hippocampus and outward differences in the dorsolateral and anterioventral regions of the hippocampus. The global cannabis-related shape difference was characterized by a large effect (Cohen's $d=1.34$).

The posthoc differences between SCZ and CON revealed a main effect for group ($F_{1,67}=5.5, p=0.02$) and a group-by-PC interaction ($F_{9,59}=2.2, p=0.03$). SCZ were characterized by inward differences in the mediodorsal region of the hippocampus as well as the anterior and posterior regions of the ventral hippocampus with outward differences observed in the dorsolateral and dorsal anterior regions of the hippocampus (Figure 1B). The global schizophrenia-related shape difference was characterized by a large effect (Cohen's $d=0.95$).

The posthoc comparison of SCZ-CUD and SCZ revealed that the main effect for group and the group- by-PC interaction were non-significant ($p>0.10$). The primary analysis observed a trend-level group-by- hemisphere interaction. As a secondary evaluation, we observed a significant group-by-hemisphere interaction ($F_{1,37}=5.6, p=0.02$). Based on this group-by-hemisphere interaction, SCZ-CUD were characterized by inward differences in the anterior, posterior, and lateral regions of the hippocampus that were most prominent in the left hemisphere (Figure 1C). The global cannabis-related shape difference was characterized by a large effect (Cohen's $d=0.90$).

The posthoc comparison of SCZ and CON-CUD did not reveal a main effect for group or group-by-PC interactions ($p>0.10$).

The covariates for the above reported shape analyses included total brain volume, total cigarettes in the past year, and verbal IQ. Across all four groups, the RM-ANOVA revealed significant hemisphere-by- nicotine use and PC-by-total brain volume interactions (both $p<0.05$). The RM-ANOVAs evaluating the post-hoc CON and CON-CUD, SCZ and CON, SCZ and CON-CUD, and SCZ-CUD and SCZ comparisons all revealed significant PC-by-total brain volume interactions (all $p<0.05$). The SCZ and CON comparison revealed a significant verbal IQ-by-PC interaction ($p<0.05$). The SCZ-CUD and SCZ comparison revealed a significant (second generation antipsychotic) dose-year-by-PC interaction ($p<0.05$). All other covariate effects were non-significant.

Hippocampal Volume

RM-ANOVAs to determine between-group differences in hippocampal volume revealed a Right>Left asymmetry for each between-group comparison (all $p<0.001$). The main effects of group and the group- by-hemisphere interaction were not significant for any comparison ($p>0.10$) (Table 2). Although the group- by-hemisphere interaction was non-significant ($p=0.12$), percent differences in volume (and effect sizes) are reported to generate hypotheses for future research. The hippocampal volume was greater in CON- CUD compared to CON in the right (percent difference: +5.68%, $d=0.42$), but not the left (percent difference: +2.62%, $d=0.20$) hemisphere. Although the main effect of group was non-significant ($p=0.16$), the hippocampal volume was lower in SCZ-CUD compared to SCZ in the left (percent difference: -8.11%, $d= -0.62$), but not the right (percent difference: -4.58%, $d= -0.31$) hemisphere. Nicotine use and dose- years of second generation antipsychotic medication use were not significant covariates (both $p>0.10$).

Between-Group Differences on Episodic Memory Performance and Symptoms

EM performance significantly differed across all four groups ($F_{3,93}=28.94, p<0.001$). CON-CUD scored lower than CON ($p=0.04, d= -0.77$), while SCZ-CUD scored lower than SCZ at the trend level ($p=0.07, d= -0.53$). CON-CUD scored higher than SCZ ($p<0.01, d=1.01$) (Figure 2, Table 3). Nicotine use and dose- years of atypical antipsychotic medication use (SCZ only) were not significant covariates (both $p>0.10$) and were removed from the EM analyses.

SCZ-CUD scored significantly higher on avolition than SCZ ($F_{2,40}=6.53, p=0.02$), which was characterized by a large effect size ($d=0.83$) after covarying for dose-years of atypical antipsychotic treatment. The remaining symptom ratings did not differ between groups (all $p>0.10$) (Table 3).

Correlations between Hippocampal Shape and Episodic Memory, Symptoms, and CUD History

Among CON-CUD and CON, a more ‘cannabis-like’ shape in the left hemisphere was correlated with poorer EM ($r = -0.25, p=0.04$). Among CON-CUD, a longer duration of cannabis abuse was correlated with ‘cannabis-like’ shape in the right hemisphere at moderate magnitudes ($r = -0.42$ to -0.48), but the results did not attain statistical significance (all $p>0.10$). No other pairwise correlation among CUD history, EM, and hippocampal shape were significant (all $p>0.10$). Among SCZ-CUD, we observed that greater duration of CUD was associated with a more ‘cannabis-like’ shape in the right hemisphere ($r=0.50, p=0.04$), and a greater duration of abstinence from CUD was associated with a less ‘cannabis-like’ shape in the left hemisphere ($r = -0.57, p=0.03$). Remaining pairwise correlations among CUD history, EM, symptoms, and hippocampal shape were non-significant (all $p>0.10$). Among SCZ and CON, we observed that a more ‘schizophrenia-like’ shape in the left hemisphere was associated with poorer EM ($r = -0.35, p=0.003$), while we did not observe a significant correlation between hippocampal shape and avolition within SCZ (all $p>0.10$).

Discussion

The current study examined whether a prior history of CUD was associated with alterations in hippocampal morphology and EM in otherwise healthy individuals and individuals with schizophrenia. The results suggest that the hippocampus in (1) CON-CUD subjects was characterized by both inward and outward surface shape differences compared to CON; (2) SCZ-CUD subjects was characterized by inward surface shape differences that were consistent with SCZ as well as distinct from both CON-CUD and SCZ. However, we did not find differences in SCZ-CUD that were observed among CON-CUD; and (3) SCZ subjects was characterized by surface shape differences that were partially consistent with prior studies. We also observed that CON-CUD and SCZ-CUD subjects demonstrated parametric deficits in EM compared to CON and SCZ, respectively. Moreover, ‘cannabis-like’ hippocampal shape was correlated with poorer EM among CON and CON-CUD, but not among SCZ and SCZ-CUD. Lastly, a longer duration of CUD abuse and a shorter duration of CUD abstinence were correlated with more ‘cannabis-like’ surface shape in schizophrenia subjects.

A past CUD diagnosis among controls was associated with both inward and outward shape differences. The observed inward shape differences are localized to regions where schizophrenia subjects are typically characterized by inward shape differences that may represent localized volume loss (Csernansky et al., 2002; Johnson et al., 2013; Mamah et al., 2010). This view is consistent with the current data indicating hippocampal shape did not differ between the CON-CUD and SCZ groups. The inward shape differences observed in

this sample are also consistent with the results of a prior study suggesting that cannabis use is related to deflation of the hippocampal surface (Solowij et al., 2013). Other research suggests that hippocampal volume among heavy cannabis using adolescents was reduced compared to nonusers (Ashtari et al., 2011), however, results in the current study regarding volume were inconclusive. A number of variables may explain the divergence between the observed shape and volume, such as the quantity, frequency, or duration that cannabis was used, duration of abstinence, and the age of CUD onset.

A past CUD diagnosis among schizophrenia subjects was associated with inward shape differences in the left hippocampus that may reflect localized volume loss. This interpretation is consistent with the moderately sized volume difference in the left hemisphere observed between schizophrenia subjects with and without a prior CUD. These observations could potentially reflect neurotoxicity within the hippocampus that has been suggested via meta-analysis (Rocchetti et al., 2013) and is consistent with prior research on cannabis-related hippocampal morphology in schizophrenia (Solowij et al., 2013). Based on the global shape difference effect size, CON-CUD and SCZ-CUD appear to have a similar degree of sensitivity to the effects of cannabis. However, the visual maps suggest that the global shape difference is qualitatively different between CON-CUD and SCZ-CUD. Also, we found an interaction between treatment with antipsychotic medications and hippocampal shape (but not volume), which is partially consistent with prior research (Fusar-Poli et al., 2013; Lesh et al., 2015; Vita et al., 2012). Perhaps greater statistical power is needed to observe a relationship between antipsychotic medication treatment and volume.

We observed a general finding that all groups were characterized by Right>Left hippocampal volume, which is a trend typically found in the healthy human brain (Pedraza et al., 2004; Woolard and Heckers, 2012), but also exaggerated in schizophrenia subjects (Breier et al., 1992; Wang et al., 2001). Interesting asymmetric shape findings were noted in SCZ-CUD where shape differences were more prominent in the left rather than right hemisphere. It appears a history of CUD may exaggerate the selective left hemisphere disruption caused by schizophrenia.

The observed hippocampal shape characterizing the SCZ group in this study was consistent with some (Johnson et al., 2013; Mamah et al., 2012; Qiu et al., 2013), but not all prior research (Csernansky et al., 2002; Johnson et al., 2013; Mamah et al., 2010). Noted differences may be reflective of prior studies evaluating schizophrenia subjects (and controls) with and without a past history of a substance use disorder as individual cohorts. Also, the observed patterns of morphology were characterized using cross-sectional data, and as such, could reflect neurobiological susceptibilities to cannabis abuse. Thus, longitudinal research is needed to determine the direction of these relationships.

The lower EM observed in both CUD groups was consistent with known effects of acute and chronic cannabis use (see (Crane et al., 2013; Ranganathan and D'Souza, 2006) for review). We observed that a more “cannabis-like” shape was related to poorer EM for CON-CUD. This may implicate that the near-daily use of cannabis during adolescence potentially interfered with synaptic pruning of the hippocampus during neuromaturation (Lisdahl et al., 2013) (CON-CUD in our study started cannabis at an average age of 16.7 years and 80%

were daily users). In turn, the potential morphometric difference may have contributed to poorer EM that persisted even after two years of abstinence. Alternatively, shape differences may represent a vulnerability biomarker of poor memory given the cross-sectional nature of the data.

Among SCZ-CUD, we observed that a longer duration of CUD abuse and a shorter duration of abstinence were both associated with a more “cannabis-like” hippocampal shape, while we did not observe any relationships between hippocampal morphology and CUD history among CON-CUD. Low statistical power could explain the lack of significance that we observed in the moderately-sized correlations between CUD history and shape among CON-CUD. An alternative explanation is that the observed morphological differences may represent neurobiological vulnerabilities to the effects of cannabis that predated cannabis use and could explain the non-significant relationships.

There are several limitations to this study. Primarily, there is an inability to infer a causal relationship between past history of cannabis use and chronically impaired EM or differences in hippocampal morphology given the cross-sectional nature of the data. Furthermore, a larger sample may provide additional statistical power necessary to determine whether the moderately-sized correlations were significant. We did not collect quantitative or biological markers of cannabis use, which could support an assessment of dose-response effects on both the hippocampus and EM, and there was no collection of treatment data other than antipsychotic medication. Along these lines, the CUD history data was collected during self-reported clinical interviews and is susceptible to the known limitations of self-report. Lastly, three CON-CUD subjects had lifetime histories of abuse of alcohol and/or other illicit substances. The analytic findings remained after excluding these subjects, thus they were included to optimize statistical power. Future research might consider longitudinal evaluations of whether cannabis-related hippocampal differences abate after a period of abstinence.

To conclude, the results suggest that a past CUD during adolescence may be associated with hippocampal morphology and EM impairments in young adulthood even after a prolonged period of abstinence. Although the results may be compatible with a causal hypothesis, the cross-sectional nature of the study does not support testing causal relationships. Hence, the observed morphological differences could be explained as biomarkers of a neurobiological vulnerability to poor memory or the effects of cannabis. Overall, there is still much to learn about the potential long-term implications of cannabis on cognition even after a period of abstinence.

Acknowledgments

Support for the collection of study data was provided by grants to Dr. Csernansky (R01 MH056584, P50 MH071616) from the National Institute of Mental Health. The Department of Psychiatry and Behavioral Sciences at Northwestern University Feinberg School of Medicine and the Warren Wright Adolescent Center at Northwestern Medicine's Stone Institute of Psychiatry provided additional support for manuscript preparation. The authors acknowledge research staff at Northwestern University's Schizophrenia Research Group and Washington University's Conte Center for data collection and database management.

Grant Sponsor: National Institute of Mental Health; Grant Number: R01 MH056584

Grant Sponsor: National Institute of Mental Health; Grant Number: P50 MH071616

References

- Andreasen, NC. The Scale for the Assessment of Negative Symptoms. Iowa City, IA: The University of Iowa; 1983a.
- Andreasen, NC. The Scale for the Assessment of Positive Symptoms. Iowa City, IA: The University of Iowa; 1983b.
- Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. *Biol Psychiatry*. 2010; 67(3):255–62. [PubMed: 19897178]
- Ashtari M, Avants B, Cyckowski L, Cervellione KL, Roofeh D, Cook P, Gee J, Sevy S, Kumra S. Medial temporal structures and memory functions in adolescents with heavy cannabis use. *Journal of Psychiatric Research*. 2011; 45(8):1055–1066. [PubMed: 21296361]
- Block RI, O'Leary DS, Ehrhardt JC, Augustinack JC, Ghoneim MM, Arndt S, Hall JA. Effects of frequent marijuana use on brain tissue volume and composition. *Neuroreport*. 2000; 11(3):491–6. [PubMed: 10718301]
- Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. *Arch Gen Psychiatry*. 1992; 49(12):921–6. [PubMed: 1449382]
- Brody AL, Mandelkern MA, Jarvik ME, Lee GS, Smith EC, Huang JC, Bota RG, Bartzokis G, London ED. Differences between smokers and nonsmokers in regional gray matter volumes and densities. *Biol Psychiatry*. 2004; 55(1):77–84. [PubMed: 14706428]
- Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, Snyder AZ. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. *Neuroimage*. 2004; 23(2):724–38. [PubMed: 15488422]
- Crane NA, Schuster RM, Gonzalez R. Preliminary Evidence for a Sex-Specific Relationship between Amount of Cannabis Use and Neurocognitive Performance in Young Adult Cannabis Users. *Journal of the International Neuropsychological Society*. 2013; 19(09):1009–1015. [PubMed: 23962414]
- Csernansky JG, Wang L, Jones D, Rastogi-Cruz D, Posener JA, Heydebrand G, Miller JP, Miller MI. Hippocampal deformities in schizophrenia characterized by high dimensional brain mapping. *Am J Psychiatry*. 2002; 159(12):2000–6. [PubMed: 12450948]
- Csernansky JG, Wang L, Joshi SC, Ratnanather JT, Miller MI. Computational anatomy and neuropsychiatric disease: probabilistic assessment of variation and statistical inference of group difference, hemispheric asymmetry, and time-dependent change. *Neuroimage*. 2004; 23(Suppl 1):S56–68. [PubMed: 15501101]
- Enders, CK. Applied missing data analysis. New York: Guildford Press; 2010.
- First, MB.; Spitzer, RL.; Miriam, G.; Williams, JBW. Structured clinical interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
- Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. *Neurosci Biobehav Rev*. 2013; 37(8):1680–91. [PubMed: 23769814]
- Heckers S, Konradi C. Hippocampal pathology in schizophrenia. *Curr Top Behav Neurosci*. 2010; 4:529–53. [PubMed: 21312412]
- Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. *Neuropsychopharmacology*. 2006; 31(12):2748–57. [PubMed: 16936704]
- Johnson SL, Wang L, Alpert KI, Greenstein D, Clasen L, Lalonde F, Miller R, Rapoport J, Gogtay N. Hippocampal shape abnormalities of patients with childhood-onset schizophrenia and their unaffected siblings. *J Am Acad Child Adolesc Psychiatry*. 2013; 52(5):527–536 e2. [PubMed: 23622854]

- Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. *Psychopharmacology (Berl)*. 2008; 199(1):89–98. [PubMed: 18548234]
- Karnik-Henry MS, Wang L, Barch DM, Harms MP, Campanella C, Csernansky JG. Medial temporal lobe structure and cognition in individuals with schizophrenia and in their non- psychotic siblings. *Schizophr Res*. 2012; 138(2-3):128–35. [PubMed: 22542243]
- Leavitt VM, Goldberg TE. Episodic memory in schizophrenia. *Neuropsychol Rev*. 2009; 19(3):312–23. [PubMed: 19639413]
- Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JH, Minzenberg MJ, Ragland JD, Solomon M, Carter CS. A Multimodal Analysis of Antipsychotic Effects on Brain Structure and Function in First- Episode Schizophrenia. *JAMA Psychiatry*. 2015
- Lisdahl KM, Gilbert ER, Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. *Front Psychiatry*. 2013; 4:53. [PubMed: 23847550]
- Mamah D, Harms MP, Barch D, Styner M, Lieberman JA, Wang L. Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness. *Front Psychiatry*. 2012; 3:96. [PubMed: 23162479]
- Mamah D, Wang L, Csernansky JG, Rice JP, Smith M, Barch DM. Morphometry of the hippocampus and amygdala in bipolar disorder and schizophrenia. *Bipolar Disord*. 2010; 12(3):341–3. [PubMed: 20565442]
- Medina KL, Nagel BJ, Park A, McQueeney T, Tapert SF. Depressive symptoms in adolescents: associations with white matter volume and marijuana use. *J Child Psychol Psychiatry*. 2007; 48(6): 592–600. [PubMed: 17537075]
- Navakkode S, Korte M. Pharmacological activation of CB1 receptor modulates long term potentiation by interfering with protein synthesis. *Neuropharmacology*. 2014; 79:525–33. [PubMed: 24412673]
- Pedraza O, Bowers D, Gilmore R. Asymmetry of the hippocampus and amygdala in MRI volumetric measurements of normal adults. *J Int Neuropsychol Soc*. 2004; 10(5):664–78. [PubMed: 15327714]
- Qiu A, Gan SC, Wang Y, Sim K. Amygdala-hippocampal shape and cortical thickness abnormalities in first-episode schizophrenia and mania. *Psychol Med*. 2013; 43(7):1353–63. [PubMed: 23186886]
- Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. *Psychopharmacology (Berl)*. 2006; 188(4):425–44. [PubMed: 17019571]
- Rocchetti M, Crescini A, Borgwardt S, Caverzasi E, Politi P, Atakan Z, Fusar-Poli P. Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. *Psychiatry Clin Neurosci*. 2013; 67(7):483–92. [PubMed: 24118193]
- SAMSHA SAAHSA. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Office of Applied Studies, DHHS Publication No. SMA 11-4658; Rockville, MD: 2011. <http://www.oas.samhsa.gov/NSDUH/2k5nsduh/tabs/2k5Tabs.pdf>
- Schobel SA, Lewandowski NM, Corcoran CM, et al. Differential targeting of the ca1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. *Archives of General Psychiatry*. 2009; 66(9):938–946. [PubMed: 19736350]
- Schoenberg MR, Duff K, Scott JG, Adams RL. An evaluation of the clinical utility of the OPIE-3 as an estimate of premorbid WAIS-III FSIQ. *Clin Neuropsychol*. 2003; 17(3):308–21. [PubMed: 14704882]
- Schuermeier J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min SJ, Sakai JT. Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003-11. *Drug Alcohol Depend*. 2014; 140:145–55. [PubMed: 24837585]
- Schumann CM, Hamstra J, Goodlin-Jones BL, Kwon H, Reiss AL, Amaral DG. Hippocampal size positively correlates with verbal IQ in male children. *Hippocampus*. 2007; 17(6):486–93. [PubMed: 17407128]
- Smith MJ, Barch DM, Wolf TJ, Mamah D, Csernansky JG. Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. *Schizophr Res*. 2008; 106(2- 3):294–9. [PubMed: 18774264]

- Smith MJ, Cobia DJ, Wang L, Alpert KI, Cronenwett WJ, Goldman MB, Mamah D, Barch DM, Breiter HC, Csernansky JG. Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. *Schizophr Bull.* 2014; 40(2):287–99. [PubMed: 24342821]
- Solowij N, Walterfang M, Lubman DI, Whittle S, Lorenzetti V, Styner M, Velakoulis D, Pantelis C, Yucel M. Alteration to hippocampal shape in cannabis users with and without schizophrenia. *Schizophr Res.* 2013; 143(1):179–84. [PubMed: 23201308]
- Stark, C. Functional role of the hippocampus. In: Anderson, P., editor. *The Hippocampus Book*. New York, NY: Oxford University Press; 2007.
- Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. *Pharmacol Biochem Behav.* 2008; 90(4):501–11. [PubMed: 18584858]
- Tzilos GK, Cintron CB, Wood JBR, Simpson NS, Young AD, Pope HG, Yurgelun-Todd DA. Lack of hippocampal volume change in long-term heavy cannabis users. *The American Journal on Addictions.* 2005; 14:64–72.
- Venkatesan R, Haacke EM. Role of high resolution in magnetic resonance (MR) imaging: Applications for MR angiography, intracranial T1-weighted imaging, and image interpolation. *International Journal of Imaging Systems Technology.* 1997; 8:529–543.
- Vita A, De Peri L, Deste G, Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. *Transl Psychiatry.* 2012; 2:e190. [PubMed: 23168990]
- Wang L, Joshi SC, Miller MI, Csernansky JG. Statistical analysis of hippocampal asymmetry in schizophrenia. *Neuroimage.* 2001; 14(3):531–45. [PubMed: 11506528]
- Wechsler, D. *Wechsler Memory Scale – Third Edition*. San Antonio: The Psychological Corporation; 1997.
- Woolard AA, Heckers S. Anatomical and functional correlates of human hippocampal volume asymmetry. *Psychiatry Res.* 2012; 201(1):48–53. [PubMed: 22285719]
- Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fornito A, Wood SJ, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. *Schizophr Bull.* 2012; 38(2):316–30. [PubMed: 20660494]
- Yucel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, Lubman DI. Regional brain abnormalities associated with long-term heavy cannabis use. *Arch Gen Psychiatry.* 2008; 65(6): 694–701. [PubMed: 18519827]

Figure 1. Hippocampal Surface Shape. Row A - cannabis-related shape in control subjects; Row B - schizophrenia-related shape; Row C - cannabis-related shape in schizophrenia subjects. T-values with cooler colors ($t < 0$) indicate inward shape differences and warmer colors ($t > 0$) indicate outward shape differences.

Figure 2.
Between-group differences in episodic memory (with standard error bars).

Table 1
Background Characteristics of Study Sample

	CON (n=44)	CON-CUD (n=10)	SCZ (n=28)	SCZ-CUD (n=15)
Demographic				
Age, mean (SD), y	25.0 (6.7)	25.2 (10.6)	27.3 (7.6)	25.3 (8.8)
Duration of Illness, mean (SD), y	--	--	7.0 (7.3)	5.4 (8.1)
Gender, No. (% male)	22 (50.0%)	5 (50.0%)	17 (60.7%)	10 (66.7%)
Handedness, mean (SD)	0.8 (0.3)	0.7 (0.2)	0.6 (0.5)	0.8 (0.2)
SES, mean (SD)	3.0 (0.9)	2.7 (0.9)	3.4 (1.1)	3.3 (1.1)
Cigarettes Smoked, mean (SD) (past year) **	983.6 (2185.7)	1799.9 (2007.7)	3100.6 (4329.8)	3617.8 (3105.7)
Crystallized IQ Z Score ** ^a	0.0 (1.0)	-0.26 (0.32)	-0.84 (0.90)	-1.18 (0.88)
Substance Use Disorders^b				
Cannabis, No. (%)	0 (0.0%)	10 (100%)	0 (0.0%)	15 (100%)
Cocaine, No. (%)	0 (0.0%)	3 (30.0%)	0 (0.0%)	0 (0.0%)
Hallucinogen, No. (%)	0 (0.0%)	3 (30.0%)	0 (0.0%)	0 (0.0%)
Alcohol, No. (%)	0 (0.0%)	2 (20.0%)	0 (0.0%)	0 (0.0%)
Stimulants, No. (%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)
Opioids, No. (%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)
Sedatives, No. (%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)
Cannabis Use Disorder				
% Met Criteria for DSM-IV Dependence	--	6 (60.0%)	--	66.7%
Frequency of Use (% daily use) ^c	--	8 (80.0%)	--	92.3%
Age of Onset of CUD, mean (SD), y	--	16.7 (2.5)	--	17.2 (1.8)
Duration of CUD, mean (SD), y	--	2.9 (3.1)	--	2.4 (2.0)
Duration since CUD abstinence, mean (SD), y ^d	--	2.2 (1.2)	--	2.6 (2.0)
Clinical Characteristics				
Lifetime History of Major Depressive Disorder	--	--	3 (11.1%) ^e	3 (20.0%)
Lifetime History of Anxiety Disorder	--	--	2 (7.4%) ^e	2 (13.3%)
Dose-Years First-Generation Antipsychotic Treatment	--	--	1.2 (3.3)	1.2 (2.3)
Dose-Years Second-Generation Antipsychotic Treatment	--	--	2.0 (2.8)	3.6 (3.9)

Note. An earlier version of this table was published by Smith et al., 2014 in Schizophrenia Bulletin.

Abbreviations: Control subjects with no history of substance use disorders (CON), Control subjects with a history of cannabis use disorder (CON-CUD), schizophrenia subjects with no history of substance use disorders (SCZ), schizophrenia subjects with a history of cannabis use disorder (SCZ-CUD).

**
 $p < .01$;

^a all groups Z scored using the group mean of CON, outlier excluded: 1 CON-CUD (3 SD above mean);

^b 1 CON-CUD abused alcohol, cocaine, and hallucinogens; 1 CON-CUD abused cocaine and hallucinogens; and 1 CON-CUD subject abused all substances;

^c 2 SCZ-CUD missing data on frequency of use but met criteria for dependence;

^d outliers excluded: 1 CON-CUD, subject 12 years since disorder; 2 SCZ-CUDs: 20 and 32 years since disorder;

^e data on co-morbid major depressive disorder or anxiety were not available for n=1 SCZ

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

Estimated Mean (SD) of Hippocampal Volume (mm³)

Hemi	CON		CON- CUD		Cohen's d Effect Size		SCZ		SCZ-CUD		Cohen's d Effect Size	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Hippocampus	Left	2292	303	2353	305	0.17	2399	300	2212	303	-0.62	
	Right	2702	378	2860	381	0.40	2855	417	2727	421	-0.31	

Table 3
Mean (SD) Between-Group Differences for Episodic Memory and Symptoms

	CON (n=44)	CON-CUD (n=10)	SCZ (n=28)	SCZ-CUD (n=15)	Effect Size
Episodic Memory	0.00 (1.00)	-0.77 (1.19)	-1.91 (1.06)	-2.55 (1.34)	-. ^a
Positive Symptoms					
Hallucinations	--	--	1.01 (1.47)	.82 (1.49)	-0.13 ^b
Delusions	--	--	1.67 (1.45)	1.88 (1.46)	0.14 ^b
Negative Symptoms					
Flat Affect	--	--	1.89 (1.33)	2.15 (1.34)	0.20 ^b
Alogia	--	--	1.29 (1.32)	1.79 (1.31)	0.38 ^b
Avolition	--	--	1.50 (1.24)	2.54 (1.26)	0.83 ^c
Anhedonia	--	--	1.75 (1.40)	2.00 (1.42)	0.18 ^b
Disorganized Symptoms					
Attention	--	--	1.71 (1.30)	2.14 (1.31)	0.33 ^b
Bizarre Behavior	--	--	0.34 (0.68)	0.51 (0.69)	0.25 ^b
Thought Disorder	--	--	0.79 (1.17)	0.93 (1.18)	0.12 ^b

Note. An earlier version of this table was published by Smith et al., 2014 in Schizophrenia Bulletin.

Abbreviations are explained in the first footnote to Table 1.

Note. n=1 CON-CUD, n=2 SCZ, and n=2 SCZ-CUD did not have EM data.

^a CON>CON-CUD ($p=0.04$, $d=-0.70$), SCZ ($p<0.001$, $d=1.85$) and SCZ-CUD ($p<.001$, $d=2.16$), CON-CUD>SCZ ($p=0.006$, $d=1.01$), CON-CUD>SCZ-CUD ($p<0.001$, $d=1.40$), SCZ-CUD>SCZ ($p=0.07$, $d=-0.54$);

^b SCZ-CUD and SCZ did not differ ($p>0.10$);

^c SCZ-CUD>SCZ ($p<0.05$).